| Q37056120 | Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors |
| Q38545523 | Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1. |
| Q49957735 | Current and emerging therapies for PNETs in patients with or without MEN1. |
| Q94464331 | Editorial: Early Genetic and Clinical Diagnosis in MEN1 |
| Q37785239 | Endocrine Cancer Predisposition Syndromes: Hereditary Paraganglioma, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, and Hereditary Thyroid Cancer |
| Q34167625 | Genetic screening for multiple endocrine neoplasia syndrome type 1 (MEN-1): when and how |
| Q47165101 | Hypercalcemic Disorders in Children. |
| Q43066318 | Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies |
| Q51336795 | Is Routine Screening of Young Asymptomatic MEN1 Patients Necessary? |
| Q90669649 | La néoplasie endocrinienne multiple de type 1 : mise au point après le congrès de l’ENETS 2019: Multiple Endocrine Neoplasia Type 1: Development after the ENETS 2019 Congress |
| Q33922666 | Late onset asymptomatic pancreatic neuroendocrine tumor - A case report on the phenotypic expansion for MEN1. |
| Q36377417 | MEN1 in children and adolescents: Data from patients of a regional referral center for hereditary endocrine tumors |
| Q38951675 | Multiple Endocrine Neoplasia: A Genetically Diverse Group of Familial Tumor Syndromes |
| Q38411934 | Multiple endocrine neoplasia syndromes 1 and 2: manifestations and management in childhood and adolescence |
| Q86555949 | Multiple endocrine neoplasia type 1 |
| Q28296266 | Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4) |
| Q36911589 | Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1-Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression |
| Q35661980 | Proliferation rates of multiple endocrine neoplasia type 1 (MEN1)-associated tumors |
| Q92354342 | Proposition of adjustments to the ACMG-AMP framework for the interpretation of MEN1 missense variants |
| Q90675538 | Questions and Controversies About Parathyroid Pathophysiology in Children With Multiple Endocrine Neoplasia Type 1 |
| Q57032522 | Results of Duodenopancreatic Reoperations in Multiple Endocrine Neoplasia Type 1 |
| Q50009808 | Synchronous Solid Pseudopapillary Tumor and Insulinoma in an Adolescent MEN1 Patient Presenting with Diagnostic Dilemmas |
| Q97887355 | Unusual Combination of MEN-1 and the Contiguous Gene Deletion Syndrome of CAH and Ehlers-Danlos Syndrome (CAH-X) |
| Q38852179 | Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients |